STOCK TITAN

Celcuity Inc - CELC STOCK NEWS

Welcome to our dedicated news page for Celcuity (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celcuity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celcuity's position in the market.

Rhea-AI Summary
Celcuity Inc. announces CEO Brian Sullivan will present at investor conferences to discuss targeted therapies for oncology. The presentations will be at the Needham Virtual Healthcare Conference and Stifel Virtual Targeted Oncology Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
conferences
-
Rhea-AI Summary
Celcuity Inc. announced dosing the first patient in a Phase 1b/2 trial for metastatic castration resistant prostate cancer. They raised $65 million and expect funds to last until the first half of 2026. The company presented nonclinical data showing the superior effects of gedatolisib at a recent symposium. Financially, expenses increased, leading to a net loss, but they secured significant funding for future development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.94%
Tags
-
Rhea-AI Summary
Celcuity Inc. (CELC) to release financial results for Q4 and full year 2023. Webcast scheduled for March 27, 2024, to discuss results and corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
Rhea-AI Summary
Celcuity Inc. (CELC) to participate in Leerink Partners Global Biopharma Conference 2024. CEO Brian Sullivan to present on March 13, 2024. Live webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
-
Rhea-AI Summary
Celcuity Inc. (CELC) to participate in Cowen’s 44th Annual Health Care Conference with CEO Brian Sullivan scheduled for a fireside chat. Live webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences
-
Rhea-AI Summary
Celcuity Inc. (CELC) initiates Phase 1b/2 study for gedatolisib in combination with Nubeqa® for metastatic castration resistant prostate cancer. The study aims to address the unmet needs of patients by providing a transformative therapeutic option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
Rhea-AI Summary
Celcuity Inc. appoints Eldon Mayer as Chief Commercial Officer, bringing over 30 years of biopharmaceutical commercial experience. Mayer's background includes successful launches of various drugs in different markets, making him ideal to lead the potential commercial launch of Celcuity's inaugural product, gedatolisib, a transformational therapy in multiple tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
management
-
Rhea-AI Summary
Celcuity Inc. (Nasdaq: CELC) presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines at the 2023 San Antonio Breast Cancer Symposium. Gedatolisib, a pan-PI3K/mTOR inhibitor, was found to be more cytotoxic and at least 300-fold more potent compared to single node PAM inhibitors, showing effectiveness in controlling key cellular functions required by cancer cells for energy production, molecule biosynthesis, and cell proliferation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary
Celcuity Inc. (Nasdaq: CELC) announced the availability of an abstract for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS). The abstract includes data on the potency and efficacy of gedatolisib, a pan-PI3K/mTOR (PAM) inhibitor, in breast cancer cell lines with mutated or non-mutated PAM pathway genes. Gedatolisib exhibited superior anti-proliferative and cytotoxic effects compared to other PAM inhibitors, suggesting potential for addressing drug resistance mechanisms. The company is currently conducting a Phase 3 trial evaluating gedatolisib plus fulvestrant with and without palbociclib in adults with HR+, HER2- advanced breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences clinical trial
Rhea-AI Summary
Celcuity Inc. (CELC) to participate in the 6th Annual Evercore ISI HealthCONx Conference in Miami. Brian Sullivan, Chairman, CEO, and Co-founder, to hold a fireside chat on November 29, 2023. Live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
conferences
Celcuity Inc

Nasdaq:CELC

CELC Rankings

CELC Stock Data

557.60M
14.06M
19.37%
53.67%
6.12%
Medical Laboratories
Health Care and Social Assistance
Link
United States
Minneapolis

About CELC

celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.